Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
simultaneously reaffirming its 2025 revenue guidance, highlighting real-world response rates near 50% in advanced melanoma and emphasizing improved manufacturing efficiency and global regulatory progress. At the same time, management is opting to fund growth through ongoing equity issuance rather than a sale, underscoring both its confidence in the Tumor Infiltrating Lymphocyte platform's long-term potential and the tension between internal expectations and current market skepticism about commercialization, governance, and capital allocation. We'll now examine how these updates on Amtagvi's commercial traction and governance scrutiny affect Iovance's investment narrative and risk-reward profile. Find companies with promising cash flow potential yet trading below their fair value To own Iovance today, you need to believe that Amtagvi can scale into a meaningful commercial franchise while the Tumor Infiltrating Lymphocyte platform broadens beyond melanoma, despite ongoing losses
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)GlobeNewswire
- Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 11/6/25 - Beat
IOVA
Sec Filings
- 1/9/26 - Form 8-K
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IOVA's page on the SEC website